Ligand Pharmaceuticals Inc (NASDAQ:LGND)

68.61
Delayed Data
As of Mar 23
 +0.98 / +1.45%
Today’s Change
45.25
Today|||52-Week Range
83.95
+2.71%
Year-to-Date
Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment
Mar 23 / Zacks.com - Paid Partner Content
Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II
Mar 20 / Zacks.com - Paid Partner Content
Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA
Mar 23 / Zacks.com - Paid Partner Content
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?
Mar 20 / Zacks.com - Paid Partner Content
AbbVie (ABBV) Gets FDA Rejection for Parkinson's Candidate
Mar 23 / Zacks.com - Paid Partner Content
Novartis (NVS) Oncology Drug Gets FDA Nod for Label Expansion
Mar 17 / Zacks.com - Paid Partner Content
Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study
Mar 22 / Zacks.com - Paid Partner Content
Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%
Mar 17 / Zacks.com - Paid Partner Content
Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals
Mar 22 / Zacks.com - Paid Partner Content
How Much Upside is Left in Ligand (LGND)? Wall Street Analysts Think 49.11%
Mar 17 / Zacks.com - Paid Partner Content
Gilead (GILD) Exercises Option to License Nurix's Candidate
Mar 21 / Zacks.com - Paid Partner Content
Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?
Mar 16 / Zacks.com - Paid Partner Content
4 Biotech Stocks to Consider for Your Portfolio in 2023
Mar 21 / Zacks.com - Paid Partner Content
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges
Mar 16 / Zacks.com - Paid Partner Content
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
Mar 21 / Zacks.com - Paid Partner Content